Related Experiment Video
Updated: May 31, 2026
07:22
Measuring the Motor Aspect of Cancer-Related Fatigue using a Handheld Dynamometer
Published on: February 20, 2020
Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis
Willemien P E de Kleijn1, Jolanda De Vries, Petal A H M Wijnen
1Center of Research on Psychology in Somatic Diseases (CoRPS), Department of Medical Psychology, Tilburg University, Tilburg, The Netherlands.
Respiratory Medicine
|June 25, 2011
Summary
The Minimal Clinically Important Difference (MCID) for the Fatigue Assessment Scale (FAS) in sarcoidosis patients is a 4-point change. This finding aids in tracking fatigue in clinical trials and patient management.
Area of Science:
- Pulmonary Medicine
- Clinical Research Methodology
- Patient-Reported Outcomes
Background:
- The clinical utility of questionnaires relies on their ability to predict treatment success.
- The Minimal Clinically Important Difference (MCID) quantifies clinically meaningful changes in scores.
- Fatigue is a significant concern in sarcoidosis management.
Purpose of the Study:
- To determine the MCID for the Fatigue Assessment Scale (FAS) in patients diagnosed with sarcoidosis.
- To establish a reliable measure for assessing meaningful improvement in fatigue levels.
Main Methods:
- A prospective follow-up study involved 321 outpatients with sarcoidosis.
- Anchor-based (Physical Quality of Life via ROC) and distribution-based (Effect Size, SEM) methods were employed.
- Receiver Operating Characteristic (ROC) analysis was performed using Physical Quality of Life as the anchor.
Main Results:
- The anchor-based MCID, determined via ROC analysis, was 3.5 points.
- Distribution-based methods yielded an MCID of 4.2 points (Effect Size) and 3.6 points (SEM).
- Consensus from both methods suggests a 4-point difference on the FAS.
Conclusions:
- The estimated MCID for the FAS in sarcoidosis patients is a 4-point change.
- This MCID value is applicable for monitoring fatigue in clinical trials.
- The established MCID facilitates individualized patient management for sarcoidosis.
